| Kevin Nethers, MD | |
|
14725 W Mountain View Blvd, Surprise, AZ 85374-2704 | |
| (623) 243-9077 | |
| (623) 271-9826 |
| Full Name | Kevin Nethers |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 7 Years |
| Location | 14725 W Mountain View Blvd, Surprise, Arizona |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932631009 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 62256 (Arizona) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Regency Skin Institute Pllc | 5193097665 | 10 |
News Archive
Environmental Tectonics Corporation today announced that its BioMedical Division will be exhibiting their new BARA-MED Select monoplace hyperbaric chamber. This new chamber, which is an addition to ETC's monoplace line, includes an undercarriage gurney storage for optimized space usage and features a fourth-generation, automated computerized operating system for control and recordkeeping, a passive pressure relief mattress, SMOOTH-RIDE™, and an adjustable height gurney and computerized treatment protocols.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced that it has received an opinion on its Marketing Authorisation Application (MAA) for Glybera as a potential therapy for Lipoprotein Lipase Deficiency.
Women with celiac disease present with fertility problems no more often than women in the general population, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association.
Canopus BioPharma, Inc. has announced that the South African Medicines Control Council has granted approval for a Phase II study in 30 cancer patients evaluating the protective effect of CB1400 on the gastrointestional tract from radiation-induced mucositis. This new trial is an important step forward in the development of CB1400 as a novel, preventative, anti-mucositis agent.
For the last seven years, researchers in the UPV/EHU's Department of Physical and Sports Education have been studying the hypertensive population with excess weight/obesity and sedentary habits. In a recent publication, this group has determined the state of health of this population through various key physical, physiological, clinical and nutritional markers and has separated them by sex and physical condition.
› Verified 7 days ago
| Entity Name | Regency Skin Institute Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932630563 PECOS PAC ID: 5193097665 Enrollment ID: O20170817002453 |
News Archive
Environmental Tectonics Corporation today announced that its BioMedical Division will be exhibiting their new BARA-MED Select monoplace hyperbaric chamber. This new chamber, which is an addition to ETC's monoplace line, includes an undercarriage gurney storage for optimized space usage and features a fourth-generation, automated computerized operating system for control and recordkeeping, a passive pressure relief mattress, SMOOTH-RIDE™, and an adjustable height gurney and computerized treatment protocols.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced that it has received an opinion on its Marketing Authorisation Application (MAA) for Glybera as a potential therapy for Lipoprotein Lipase Deficiency.
Women with celiac disease present with fertility problems no more often than women in the general population, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association.
Canopus BioPharma, Inc. has announced that the South African Medicines Control Council has granted approval for a Phase II study in 30 cancer patients evaluating the protective effect of CB1400 on the gastrointestional tract from radiation-induced mucositis. This new trial is an important step forward in the development of CB1400 as a novel, preventative, anti-mucositis agent.
For the last seven years, researchers in the UPV/EHU's Department of Physical and Sports Education have been studying the hypertensive population with excess weight/obesity and sedentary habits. In a recent publication, this group has determined the state of health of this population through various key physical, physiological, clinical and nutritional markers and has separated them by sex and physical condition.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kevin Nethers, MD 14725 W Mountain View Blvd, Surprise, AZ 85374-2704 Ph: (623) 243-9077 | Kevin Nethers, MD 14725 W Mountain View Blvd, Surprise, AZ 85374-2704 Ph: (623) 243-9077 |
News Archive
Environmental Tectonics Corporation today announced that its BioMedical Division will be exhibiting their new BARA-MED Select monoplace hyperbaric chamber. This new chamber, which is an addition to ETC's monoplace line, includes an undercarriage gurney storage for optimized space usage and features a fourth-generation, automated computerized operating system for control and recordkeeping, a passive pressure relief mattress, SMOOTH-RIDE™, and an adjustable height gurney and computerized treatment protocols.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced that it has received an opinion on its Marketing Authorisation Application (MAA) for Glybera as a potential therapy for Lipoprotein Lipase Deficiency.
Women with celiac disease present with fertility problems no more often than women in the general population, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association.
Canopus BioPharma, Inc. has announced that the South African Medicines Control Council has granted approval for a Phase II study in 30 cancer patients evaluating the protective effect of CB1400 on the gastrointestional tract from radiation-induced mucositis. This new trial is an important step forward in the development of CB1400 as a novel, preventative, anti-mucositis agent.
For the last seven years, researchers in the UPV/EHU's Department of Physical and Sports Education have been studying the hypertensive population with excess weight/obesity and sedentary habits. In a recent publication, this group has determined the state of health of this population through various key physical, physiological, clinical and nutritional markers and has separated them by sex and physical condition.
› Verified 7 days ago
Lynn Leroy Juracek, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 14239 W Bell Rd, Suite 101, Surprise, AZ 85374 Phone: 623-544-7755 Fax: 623-544-8665 | |
Jesse M Olmedo, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 14800 W Mountain View Blvd, Suite 160, Surprise, AZ 85374 Phone: 623-584-3376 Fax: 623-584-3375 | |
Dr. Susan Il Iorio, MD Dermatology Medicare: May Accept Medicare Assignments Practice Location: 14725 W Mountain View Blvd Ste 103, Surprise, AZ 85374 Phone: 623-243-9077 Fax: 623-544-8665 | |
Dr. Drew Aubrey Reese, D.O. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 14800 W Mountain View Blvd Ste 160, Surprise, AZ 85374 Phone: 623-584-3376 Fax: 623-584-3375 | |
Dr. James Orson Barlow, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 14800 W Mountain View Blvd Ste 160, Surprise, AZ 85374 Phone: 623-584-3376 Fax: 623-584-3375 |